India, Oct. 8 -- Shares of Glaukos Corp. (GKOS) are falling about 11 percent on Thursday morning after the company announced an exclusive licensing agreement with RevOpsis Therapeutics, Inc. to develop and commercialize RO-104, a biologic being developed for several retinal diseases.
The company's stock is currently trading at $153.65, down 10.76 percent or $18.67, over the previous close of $172.18 on the New York Stock Exchange. It has traded between $73.16 and $191.62 in the past year.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....